Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population.

导出原文传递

翻译打印收藏纠错

作者： Shana S,Jacobs ^[1] ; Jeffrey S,Dome ^[2] ; Jiaxiang,Gai ^[3] ; Andrea M,Gross ^[4] ; Elena,Postell ^[5] ; Pamela S,Hinds ^[6] ; Lionel,Davenport ^[3] ; John N,van den Anker ^[4] ; Catriona,Mowbray ^[7]

作者单位： Division of Oncology, Children's National Hospital, Washington, DC, USA. ssjacobs@childrensnational.org. ^[1] George Washington University School of Medicine and Health Sciences, Washington, DC, USA. ssjacobs@childrensnational.org. ^[2] Division of Oncology, Children's National Hospital, Washington, DC, USA. ^[3] George Washington University School of Medicine and Health Sciences, Washington, DC, USA. ^[4] Biostatistics and Study Methodology Department, Children's National Hospital, Washington, DC, USA. ^[5] Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA. ^[6] Department of Nursing Science, Professional Practice & Quality, Children's National Hospital, Washington, DC, USA. ^[7] Division of Pathology and Lab Medicine, Molecular Diagnostics, Children's National Hospital, Washington, DC, USA. ^[8] Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA. ^[9]

关键词 Chemotherapy-induced nausea Ondansetron Pediatric cancer Pharmacogenomics